How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice
1Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Abstract:
The management of chronic myeloid leukemia (CML) has remarkably changed in the last 20 years with the availability of tyrosine kinase inhibitors (TKI). Most patients with chronic phase CML now have a life expectancy like that of age matched controls. Understanding the practical aspects of choosing the appropriate TKI, monitoring response and side-effects are key to long term success. Currently, treatment cessation is also an option in patients achieving sustained deep molecular response. Novel agents are needed in patients with lack of response to TKI and in those with advanced disease.
More Related Videos
Related Concept Videos
Chronic Kidney Disease IV: Nursing Management
Differentiation of Common Myeloid Progenitor Cells
Chronic Kidney Disease II: Clinical Manifestations
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...


